Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
Earnings Data
Report Date
Oct 30, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.84Last Year’s EPS
-1.56Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlights Vir Biotechnology's significant progress in their ECLIPSE program and T cell engager portfolio, alongside a strong financial position and reduced operating expenses. However, the company continues to face challenges with net losses and estimating the HDV patient population.Company Guidance
Progress in the ECLIPSE Program
Vir Biotechnology has successfully enrolled the first patients in ECLIPSE 2 and ECLIPSE 3, with all three registrational studies actively recruiting patients globally. The primary completion for ECLIPSE 1 is expected by December 2026.
Advancements in T Cell Engager Programs
Vir has initiated a Phase I study for VIR-5525, their EGFR-targeted T cell engager, marking their third clinical stage T cell engager program. They also received IND clearance to evaluate VIR-5500 in earlier lines of prostate cancer treatment.
Strong Financial Position
Vir Biotechnology ended the second quarter with approximately $892 million in cash, cash equivalents, and investments, providing a cash runway extending into mid-2027.
Decreased Operating Expenses
Operating expenses in Q2 2025 were $119.6 million, a $42.1 million decrease from the same period in 2024, due to cost savings from restructuring initiatives and reduced stock-based compensation.
ECLIPSE Program Market Potential
The ECLIPSE program targets approximately 7 million active viremic HDV RNA-positive patients globally, with a significant concentration in major urban centers in the U.S., offering a compelling commercial opportunity.
VIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $5.08 | $4.35 | -14.37% |
May 07, 2025 | $5.61 | $5.41 | -3.57% |
Feb 26, 2025 | $9.20 | $8.11 | -11.85% |
Oct 31, 2024 | $7.49 | $9.26 | +23.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vir Biotechnology (VIR) report earnings?
Vir Biotechnology (VIR) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).
What is Vir Biotechnology (VIR) earnings time?
Vir Biotechnology (VIR) earnings time is at Oct 30, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VIR EPS forecast?
VIR EPS forecast for the fiscal quarter 2025 (Q3) is -0.84.